Pepgen inc. announces clearance of cta by health canada to begin the freedom-dm1 phase 1 study of pgn-edodm1 in patients with myotonic dystrophy type 1

The u.s. food and drug administration (fda) granted orphan drug designation to pgn-edodm1 for the treatment of myotonic dystrophy type 1 (dm1) the u.s. food and drug administration (fda) granted orphan drug designation to pgn-edodm1 for the treatment of myotonic dystrophy type 1 (dm1)

PEPG Ratings Summary

PEPG Quant Ranking